NCT05740813CompletedPhase 2/3
HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262
Source: ClinicalTrials.gov · Last updated 14 Nov 2025
Brief summary (registry, in English)
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen F will evaluate the safety and efficacy of a single study drug, ABBV-CLS-7262, in participants with ALS.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2/3
- Study type
- Interventional
- Enrollment
- 310 (actual)
- First submitted
- 12 Feb 2023
- Start date
- 23 Mar 2023
- Primary completion date
- 3 Oct 2024
- Lead sponsor
- Merit E. Cudkowicz, MD
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT05740813
What you commit to
- Study type: Interventional · Phase 2/3
- Participants enrolled: 310
- From 23 Mar 2023 to the primary completion date, 3 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT NCT04297683).
- Based on the metabolism of the compound, the concomitant use of certain inhibitors and inducers of cytochrome P450 enzymes.
- Any clinically significant ECG abnormalities.
- Clinically significant clinical laboratory abnormalities.
Who the study is looking for
- No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT NCT04297683).
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Healey Center for ALS at Mass General Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.